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Since the development of Vaccinia virus as a vaccine vector in 1984, the utility of 
numerous viruses in vaccination strategies has been explored. In recent years, key 
improvements to existing vectors such as those based on adenovirus have led to 
significant improvements in immunogenicity and efficacy. Furthermore, exciting new 
vectors that exploit viruses such as cytomegalovirus and vesicular stomatitis virus 
have emerged. Herein, we summarize these recent developments in viral vector 
technologies and discuss the potential utility of these exciting approaches in eliciting 
protection against infectious diseases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
Recombinant viral vectors represent promising vaccine platforms due to their ability 
to express heterologous antigens and induce antigen6specific cellular immune 
responses in addition to robust antibody titers, without the need for exogenous 
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adjuvants. Vaccinia virus was the first virus to be developed as a vaccine vector (1), 
and numerous others have since been explored as delivery vehicles for foreign 
immunogens. Here, we discuss a selection of novel vaccine vectors that have 
entered clinical trials recently and/or are forerunners for licensure. As a number of 
other viral vectors have already been comprehensively reviewed ((2) (3) (4) (5) (6) 
(7)), we will not discuss these further.  


	
Human cytomegalovirus (HCMV) is a beta6herpesvirus with a large (236 kbp) DNA 
genome that establishes life6long, usually asymptomatic, infection in healthy 
individuals. Significant interest in harnessing HCMV in vaccine vector development 
has stemmed from the observation that HCMV induces unusually large T cell 
responses (reviewed elsewhere (8)). Natural infection with HCMV elicits broad T cell 
responses directed to a vast array of antigens, with HCMV6specific responses 
comprising ~10% of the entire CD4+ and CD8+ T cell memory compartments (9). 
Although HCMV employs a vast array of immune evasion strategies to avoid control 
by the host immune system (reviewed in (10, 11)), HCMV6specific T cell responses 
are long6lived, with particularly high frequencies in elderly individuals (12). HCMV6
specific T cells also maintain functionality during virus chronicity and readily produce 
multiple effector molecules (e.g. IFN6γ, TNFα) upon stimulation (13) (14) and control 
virus replication  (15). Furthermore, experiments in the murine CMV (mCMV) 
model that recapitulates the accumulation of highly functional CMV6specific T cell 
over time (16) (17) (18) demonstrate that CMV infection triggers seeding of tissue6
resident memory T cells in peripheral, including mucosal, tissues (19) (20). Thus, 
although HCMV also induces substantial antibody responses upon infection (21), this 
virus represents a particularly exciting tool for inducing potent T cell immunity.  
 
HCMV exhibits several other properties attractive for viral vectors. CMV6based 
vectors can be engineered to express multiple exogenous immunogens (22) (23). 
HCMV also super6infects HCMV immune hosts (24). The immunogenicity of CMV6
based vaccines was first investigated using recombinant mCMV6based constructs. 
These induced accumulation of T cells reactive to peptides derived from 
heterologous antigens that, importantly, conferred protection from heterologous 
(vaccinia) viral challenge (25). Subsequently, induction of protective pathogen6
specific T cell responses by mCMV6based vectors has been demonstrated in 
ebolavirus, herpes simplex virus and 	


challenge models 
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(26) (27) (28) (29), although non6specific induction of NK cell responses partially 
contributes to early anti6mycobacterial activity of mCMV (28).  
 
Broad interest in HCMV6based vaccines was triggered by encouraging data from 
rhesus CMV (RhCMV)6based vaccines engineered to express antigens from simian 
immunodeficiency virus (SIV). Using vectors expressing SIV Gag, Env and a Rev6
Tat6Nef fusion protein, Picker and colleagues demonstrated vaccine6induced 
protection from mucosal SIV challenge that was associated with the development of 
effector memory T cell responses (22) (23). Whilst RhCMV6induced protection did 
not preclude SIV spread from mucosal sites of entry, progressive clearance of SIV in 
~50% macaques was reported, providing evidence that CMV6based vaccines may be 
exploited to induce protective anti6HIV immunity (30) (31).  
 
Analysis of RhCMV vaccine6induced T cell immunity revealed broad CD8+ T cell 
responses with an altered epitope hierarchy to responses induced by natural SIV 
infection. Intriguingly, RhCMV6induced CD8+ T cells were restricted by MHC class II 
(30) and HLA6E (32) rather than through classical MHC6Ia restriction. This unique 
induction of CD8+ T cell responses was attributed to deletion of the Rh157.5/4 genes 
within the fibroblast6adapted RhCMV vector (32). Rh157.5/4 are orthologs of the 
HCMV UL128/UL130 genes that encode components of the viral pentameric 
complex that is required for viral entry into non6fibroblast cells (33). How deletion of 
these genes leads to the induction of unique T cell responses is unclear. 
Interestingly, in a phase I trial in humans using chimeric HCMV viruses that lacked 
the pentameric complex, vaccine6induced CD8+ T cell responses exhibited classical 
MHC restriction (34). This may indicate key biological differences between RhCMV 
and HCMV, or may reflect the incomplete understanding of how RhCMV vectors elicit 
their unusual responses. It will be important to define the mechanisms that underpin 
the induction of these unusual T6cell responses, and to identify which responses are 
critical for protection, in order to generate human CMV vectors that are equally 
effective. 
 
CMV6based vectors are clearly exciting. However, HCMV is pathogenic, and 
attenuated vectors are necessary for translation into humans. In mice, temperature 
sensitive mCMV fails to induce robust virus6specific CD8+ T cell memory (35), 
eliminating this strategy from exploration for vector attenuation. Encouragingly, 
however, spread6deficient mCMV vectors lacking the surface glycoprotein L (36) or 
the virion protein M94 (37) induce robust T cell immunity. Indeed, glycoprotein L6
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deficient (gL) mCMV induces circulating effector memory6like CD8+ T cell 
responses, although the degree to which different mCMV6specific responses are 
induced varies substantially (36). Whether variation reflects the differential 
dependence of mCMV6specific CD8+ T cells on CD4+ T cell help (38) (39) (40) is 
unclear. Importantly, we observed that gL deficiency substantially impairs the 
seeding of multiple epitope6specific CD8+ T cell responses within peripheral tissues, 
and gL mCMV6induced CD8+ T cells exhibit sub6optimal recall responsiveness (Ian 
R Humphreys, unpublished observation). Thus, a greater understanding of how to 
safely induce potent T cell responses using CMV6based vectors will inform future 
strategies.  
 
Studying CMV6induced T cell immunity may also inform alternate vector6based 
vaccine strategies. Experiments with mCMV have suggested that antigen expression 
rather than peptide6intrinsic properties influence mCMV6induced T cell expansions 
(29). Furthermore, C6terminal localization of peptide in viral proteins greatly 
increases peptide availability for proteosomal processing and subsequent 
accumulation of protective peptide6specific T cell memory (41). Interestingly, 
adenovirus6based vectors engineered to express peptide mini6genes can induce 
effector memory T cell accumulations indicative of CMV6induced T cell immunity (42) 
(43). Thus, studies of CMV6induced T cell responses may inform the development of 
alternate viral vector systems capable of inducing robust effector memory T cell 
responses.  




	
	

Soon after their pioneering development as gene therapy vectors in the early 1990s, 
adenoviruses were also explored as vaccine vectors (44) and have been used in 
numerous clinical vaccine trials since 2003 (45). Thus, they are not considered novel 
vectors . However, in the past few years, several groups have made innovative 
improvements to adenoviral vectors which are worth exploring here as these are 
already, or have the potential to become, clinically relevant. The various 
enhancements broadly address two challenges: (i) overcoming pre6existing anti6
vector immunity and (ii) enhancing vaccine6induced antigen6specific immunogenicity. 
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Adenoviruses (Ads) are non6enveloped icosahedral viruses with 30640 kb linear DNA 
genomes, which can be genetically manipulated without difficulty. The antigen 
expression cassette is most often inserted into the E1 genomic locus, rendering the 
virus replication6deficient. Vectors in which nonessential E3 genes are also deleted 
can accommodate expression cassettes up to a size of 7 kb. Until recently, 
replication6deficient AdHu5 was the most widely used Ad vector in vaccine 
development, due to its ability to elicit exceptionally strong CD8+ T6cell and antibody 
responses, and the ability to generate high titers of virus during manufacturing. 
However, pre6existing immunity against this vector, specifically neutralizing antibody 
titer, was shown to correlate with a reduction in antigen6specific immunogenicity in 
clinical trials (46) (47). Many groups consequently explored adenoviruses with lower 
seroprevalence in the human population, such as different human Ad serotypes or 
simian Ads. Interestingly, different serotypes were found to elicit different 
immunogenicity profiles in mice with respect to phenotype, function and longevity of 
the cellular immune response (48). For example, the human adenoviral vectors Ad26 
and Ad35 induced enhanced memory CD8+ T cells and more polyfunctional CD8+ T 
cells as compared to Ad5 (48). These two alternative vectors (Ad26 and Ad35) have 
also been evaluated in clinical trials, with variable outcomes (49) (50) (51) (52). For 
example, Ad26 and Ad35 vectors containing the HIV61 env antigen were used in 
heterologous prime6boost combinations in a Phase I trial (53). The authors found that 
the Ad266Ad35 prime6boost elicited significantly higher antibody titers than the Ad356
Ad26 regimen, but T6cell responses were modest overall. Ad26 was also used as a 
priming vector in Ebola clinical trials, where together with an MVA boost, vaccination 
was able to elicit a strong and durable antibody response to the Ebola virus antigen 
(54) (55). Ad35 has additionally been evaluated in several other HIV vaccine trials 
(56) (51) (57) (58), where it was demonstrated to be safe and immunogenic. 
Furthermore, in a TB vaccine trial it was found to be safe in both infants and HIV+/6 
adults. However, it only elicited a cellular immune response upon repeated high dose 
vaccinations (49). 
 
In addition to human Ads, many simian Ad6based vaccine vectors have been tested 
pre6clinically, and five have advanced to clinical studies to date (59) (60) (61), with 
promising results. A prominent example is ChAd36EBOZ, a chimpanzee6adenoviral 
vector encoding the Ebola Zaire glycoprotein, which was evaluated in Phase I and II 
clinical trials in response to the recent Ebola epidemic (62) (63) (64). This vector was 
assessed with and without an MVA booster dose, and was found to elicit strong 
antibody and T6cell responses which could be increased in magnitude and durability 
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by an MVA boost. Another chimpanzee adenoviral vector, ChAd63, has also been 
evaluated in several clinical trials (malaria (65) (66) (67), leishmaniasis (68)) with 
results showing excellent safety and immunogenicity, even in infants and children. 
 
Improving transgene immunogenicity is also a significant focus of on6going studies. 
One strategy to enhance the immune response against exogenous antigen is to 
increase immunogen production from the vaccine vector. This is difficult to achieve 
with replication6deficient (E16deleted) Ad vectors, since antigen expression is 
restricted to the single copy of the vector genome present in the infected target cell. 
Increased antigen expression could be achieved by enabling the vector to self6
amplify in one additional round of genome replication after cell entry (so6called 
single6cycle Ads), or by using replication6competent adenoviruses. The former 
approach has been explored through deletion of a structural gene (pIIIa) from a 
replication6competent adenovirus (69) that renders the virus unable to spread. The 
subsequent virus expresses early viral genes and replicates its genome, producing 
~306100 fold more copies of the antigen expression cassette than replication6
deficient vectors. Impressively, a single6cycle Ad encoding influenza A hemagglutinin 
showed a significantly higher antibody induction than its replication6deficient 
equivalent, even at a 106fold lower dose (70, 71). One drawback of this method, 
however, is the requirement for a trans6complementing cell line (in this case 
expressing pIIIa) for the production of such a single6cycle Ad, which may represent a 
bottleneck for clinical development.  
 
To fully exploit the advantages of a self6amplifying vaccine, several groups have also 
examined the use of replication6competent Ad vectors, which were administered by 
varying mucosal routes in permissive species (mice are not permissive for human or 
simian adenoviruses.) Unfortunately, results with regard to induction of humoral 
immunity were mixed (72) (73) (74) or disappointing (75) (76) (77). One beneficial 
feature of replication6deficient adenoviral vectors is the fact that the transgene is 
typically immuno6dominant by default, since the lack of adenoviral gene expression 
precludes immune6competition. It is therefore likely that replication6competent 
vectors can only be effective vaccines if the transgene remains immuno6competent 
whilst competing with numerous other viral gene products; achieving this has been 
challenging (reviewed in (78)). Furthermore, replicating adenoviral vectors carry 
higher safety risks due to their ability to cause systemic infection in certain 
susceptible populations (79). However, whilst they are indeed not suitable for use in 
the severely immunocompromised, a live (oral) adenovirus vaccine used to protect 
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against respiratory disease caused by Ad4 and Ad7 has nevertheless long been 
used in the United States army, with a very good safety profile (80). 
 
In addition to exploiting vector amplification to increase antigen expression, several 
other methods have been described which aim to enhance the immunogenicity of 
adenoviral vectors. One of these approaches, antigen capsid6incorporation, has been 
particularly successful in preclinical studies (reviewed in (81)). Here, antigenic 
epitopes are incorporated into viral structural proteins in such a way that they are 
exposed on the virus surface and are therefore able to elicit robust antibody 
responses. Epitopes from a variety of different pathogens have been tested (e.g. 
HIV61 (82), influenza A (83),  
 (84)). One group, for example, 
demonstrated that a multivalent HIV61 vector based on AdHu5 elicited antibody 
responses to an externally presented HIV61 B6cell epitope, in addition to cellular 
response to the virally encoded HIV61 gag antigen (85). One clear disadvantage of 
this method is that only short heterologous sequences can be inserted into viral 
structural genes without affecting virus assembly or stability. As an exception, the 
adenoviral capsid protein pIX can accommodate C6terminal fusions with larger 
antigens. However, these fusions can have a destabilizing effect on the virion (86). 
Overall, considering the large numbers of publications reporting encouraging results, 
it is surprising that (to our knowledge) the capsid6display approach has not yet been 
evaluated in the clinic.  
 
 

		
The use of VSV as a vaccine vector was pioneered by Rose and colleagues in the 
late 1990s (87), and the vector has since been employed in numerous preclinical 
studies. However, due to the challenges encountered in developing a sufficiently 
attenuated, safe VSV backbone, a first6in6human evaluation of an rVSV vaccine did 
not take place until 2011 (88). This was soon followed by clinical trials of an rVSV6
vectored Ebola vaccine (2014), which was the most advanced vaccine candidate in 
the recent ebolavirus epidemic in West Africa. Buoyed by this success, the VSV 
vector has been the subject of much interest by numerous investigators.  
 
VSV is an enveloped bullet6shaped virus that belongs to the  family and 
contains an 11kb negative6sense RNA genome. Apart from its ability to induce robust 
cellular and humoral immunity against encoded transgenes, its high titer growth in 
validated cell lines (e.g. Vero) and the lack of a DNA intermediate during viral 
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replication add to its attractiveness as a vaccine vector. However, owing to its 
negative6sense RNA genome, rescue of recombinant virus from plasmid DNA is 
more challenging than rescue of DNA viruses, as it involves co6transfection of five 
plasmids into a permissive cell line (89). The cargo capacity of recombinant VSV 
vectors was found to be at least 4.5 kb (90), and its genomic structure conveniently 
allows insertion of transgenes at multiple sites, which will result in transgene 
expression at varying levels. Unlike adenoviral vectors (which are typically 
replication6deficient), most VSV vaccine vectors are replication6competent, albeit 
attenuated. Attenuation represents an important safety feature, as wild type VSV is 
neurovirulent upon intracranial inoculation (91). Attenuation of VSV can be achieved 
in several ways; the most prominent example combines down6regulation of N protein 
expression with truncation of the VSV6G cytoplasmic tail, resulting in the attenuated 
vector rVSVN4CT1, which has been approved for clinical studies (92).  
 
In the past 20 years, VSV vaccine vectors have been demonstrated to induce robust 
cellular and humoral immune response in numerous preclinical studies, leading to 
protection in many animal models of pathogen challenge, frequently after a single 
vector administration (reviewed in (93)). Durability of a protective immune response 
(up to one year thus far) has also been demonstrated (94). Since 2011, rVSV vectors 
have been evaluated in four completed or ongoing clinical trials for HIV61 (88) (95) 
(96) (97), and in Phase I and II and III trials for Ebola (reviewed in (98)).  Of note, the 
Phase III trial which took place during the 2014/15 outbreak in Guinea showed 
promising efficacy in a ring6vaccination strategy (99). Analysis of immunogenicity in 
these studies revealed a robust induction of neutralizing antibodies and a modest 
CD8+ response for all participants in the Ebola clinical trials (100), while the only 
report thus far of an HIV61 trial was more disappointing, with modest CD4+ levels in 
two thirds of participants and low antigen6specific antibody levels in one third of 
participants (88). Of interest, significant differences existed in the vector backbones 
used in these trials: rVSV6HIV61 vectors were attenuated by genetic engineering as 
mentioned above (containing the rVSVN4CT1 backbone) and the HIV61 antigen 
coding sequence was placed in position 1 of the genome. In contrast, the rVSV6
EBOV clinical vector was simply based on the cell culture adapted VSV Indiana 
strain lacking VSV6G (rVSV∆G), with the Ebola glycoprotein (EBOV6GP) placed in 
position 4. In the absence of the native glycoprotein, EBOV6GP acted as the vaccine 
antigen in addition to the viral entry protein. Since the VSV glycoprotein is the main 
determinant of viral tropism, safety considerations for the rVSV6EBOV vector are 
different than those for the rVSV6HIV vectors. Indeed, in initial Phase I trials, 
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replication of the rVSV6EBOV vector was detected in synovial fluid and skin lesions, 
most likely due to EBOV6GP specific tissue tropism (101).  
 
In an effort to address safety concerns, more attenuated, second generation rVSV6
EBOV vectors were recently developed (102). Attenuation was achieved by 
employing the rVSVN4CT1 backbone, and reduced virus growth was demonstrated 
in cell culture (102). The vaccine was still protective in a non6human primate Ebola 
challenge model after a single administration and, reassuringly, vaccination resulted 
in a 106 to 506fold reduction in vaccine6associated viremia in the blood as compared 
to first6generation vectors in previous studies. Unfortunately, this study did not 
include a direct comparison with first6generation rVSV6ZEBOV. However, a Phase I 
trial of this vaccine (rVSVN4CT16EBOVGP1) was recently completed (103), and thus 
insight into the safety profile of this vector will be soon available. In addition, 
GemEvac6Combi, an Ebola vaccine containing an rVSV expressing the Ebola GP, 
has also been developed (104). This vaccine was evaluated for safety and 
immunogenicity in a 2015 Phase I trial and subsequently licensed by the Ministry of 
Health of the Russian Federation. However, it is difficult to assess the potential 
impact of this vaccine, considering the paucity of published preclinical data and the 
lack of information regarding vector construction. A Phase 4 study of this vaccine 
involving 2,000 volunteers in Russia and Guinea is planned for 201762019  (105). 
 
In parallel with ongoing clinical studies, VSV vectors have been modified to further 
improve utility to create multivalent vectors. Mire   generated trivalent rVSV 
encoding glycoproteins from Zaire ebolavirus, Sudan ebolavirus and Marburg virus, 
and demonstrated protection against all three virus strains in a Guinea pig challenge 
model after a single immunization, even though antibody responses to each antigen 
differed in magnitude (106). Encouragingly, vectors containing ~6 kb transgenic 
cargo were generated, suggesting that multiple or large inserts can be incorporated 
into rVSV vectors. Another recent valuable observation regarding rVSV vector 
development is their ability to provide protection even after exposure to the 
pathogen. For example, full protection was shown when rhesus monkeys were 
vaccinated with an rVSV6MARV vector 30 minutes after receiving a lethal dose of 
Marburg virus (107), and five of six of animals were still protected when vaccinated 
24 hours after challenge (108). T cell depletion had no impact on vaccine6induced 
protection (109), suggesting that rapid induction of antibodies may underlie vaccine 
efficacy. Taken together, both preclinical and clinical studies suggest that the 
strengths of the VSV vector lie in its attenuated replicative capacity and its ability to 
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elicit high and durable antibody levels to surface6displayed antigens; characteristics 
which make it a promising vaccine vector for emerging or outbreak6prone viral 
diseases.    
 
 
	
Despite its pathogenicity, the development of measles virus as a vaccine vector was 
initiated in the late 1990s. This was based on the large success of the live attenuated 
measles vaccine itself. Measles vaccines were developed in the early 1960s by cell 
culture adaptation of wild type virus isolates, leading to attenuation via an 
accumulation of mutations. The most attenuated strains, still used today, have 
excellent safety profiles while still inducing extremely durable, protective antibody6 
and T6cell mediated immunity in 95% of recipients after a single vaccination (110) 
(111) (112). Interestingly, T6cell mediated responses to MV are predominantly of the 
CD4+ phenotype (113), unlike the CD8+ dominated response to adenoviral vectors 
(114), which may have important implications when considering these vector 
platforms for vaccine development.  
 
Measles virus, a member of the 	 family, is an enveloped spherical 
virus and contains a 16 kb negative6sense RNA genome. The development of 
reverse genetics tools and rescue of MV from cDNA in 1995 (115) accelerated both 
basic MV virology research and exploration of MV as a vaccine vector. Studies 
demonstrated a cargo capacity in excess of 6 kb and an excellent induction of 
humoral and cellular immune responses against encoded transgenes (116). In 
addition, MV was easily adaptable to large scale bio6manufacture, at low production 
cost. Recombinant MVs expressing one or more genes from heterologous pathogens 
have now been used in numerous preclinical vaccine studies (reviewed in (117)). 
One group, for example, generated an rMV expressing HIV61 Gag, RT and Nef as a 
fusion protein (MV16F4) and assessed immunogenicity of the vector in prime or 
prime6boost regimens in cynomolgus macaques (118). Vaccination induced robust 
antigen6specific CD4+ and modest CD8+ T6cell responses, and high levels of 
antibody reactive to exogenous antigens and MV6encoded proteins that were further 
amplified after boosting (118).  
 
During preclinical development, concerns arose regarding the impact of pre6existing 
immunity against the MV vector, as the live attenuated measles vaccine is part of 
routine childhood immunization programs in many countries. However, higher doses 
Page 11 of 55 Immunology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
or alternative administration routes of the vector can overcome existing anti6measles 
antibody levels in mice (119). Of note, in this study pre6existing immunity was 
artificially modeled using intra6venous administration of anti6measles antibodies. 
However, another study that examined prior exposure to attenuated measles vaccine 
found no influence of existing anti6MV immunity on transgene immunogenicity in 
mice or macaques (120). Another important consideration for the possible pediatric 
use of MV vectors is the requirement for the vector to retain vaccine competence 
against MV itself. This was indeed demonstrated in a macaque model using a MV6
based hepatitis B vaccine candidate (121). 
 
After almost two decades of preclinical development, MV vaccine vectors have 
recently been advanced into clinical trials, with two Phase I studies completed (HIV61 
(122), Chikungunya virus (CHIKV) (123)) and two Phase II CHIKV trials ongoing or 
planned in Europe and Puerto Rico, respectively (124) (125). In the Phase I CHIKV 
study, volunteers received escalating priming doses followed by a booster dose of an 
rMV encoding the structural genes (C, E3, E2, 6K and E1) of CHIKV, a mosquito6
borne alphavirus of the tropics and sub6tropics that is threatening to become a global 
public health burden. Protective immunity against CHIKV is antibody6mediated in a 
mouse model (126). Encouragingly, seroconversion was demonstrated for 90% of 
participants in the high dose group after one immunization, and for all participants 
after the second vaccination. In addition, immunogenicity was not affected by pre6
existing anti6measles immunity, an important finding which will hopefully be 
confirmed in larger ongoing studies. 
 
 

	 

Viral vectors hold much promise for vaccine vector development to counter infectious 
diseases. Significant advances have been made regarding the production of 
immunogenic vectors that can be used in individuals that have prior immunity to the 
viruses on which vectors are based. More detailed understanding of what immune 
responses are preferentially induced by vectors and how they are triggered will 
inform decisions as to which vectors are most relevant for vaccination against a 
specific infectious disease (Figure 1). Safety considerations remain a significant 
challenge in the development of certain viral vectors. This is relevant not only for 
vaccination against infectious diseases, but also for the potential exploitation of virus6
based vectors in cancer vaccination strategies where individuals are often immune 
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compromised. Thus, understanding better how to balance safety and immunogenicity 
will have broad implications for the management of infectious diseases and beyond. 
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Since the development of Vaccinia virus as a vaccine vector in 1984, the utility of 
numerous viruses in vaccination strategies has been explored. In recent years, key 
improvements to existing vectors such as those based on adenovirus have led to 
significant improvements in immunogenicity and efficacy. Furthermore, exciting new 
vectors that exploit viruses such as cytomegalovirus (CMV) and vesicular stomatitis 
virus (VSV) have emerged. Herein, we summarize these recent developments in viral 
vector technologies, focusing on novel vectors based on CMV, VSV, measles and 
modified adenovirus. We discuss the potential utility of these exciting approaches in 
eliciting protection against infectious diseases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
Recombinant viral vectors represent promising vaccine platforms due to their ability 
to express heterologous antigens and induce antigen7specific cellular immune 
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responses in addition to robust antibody titers, without the need for exogenous 
adjuvants. Vaccinia virus was the first virus to be developed as a vaccine vector (1), 
and numerous others have since been explored as delivery vehicles for foreign 
immunogens. Here, we discuss a selection of novel vaccine vectors that have 
entered clinical trials recently and/or are forerunners for licensure. As a number of 
other viral vectors have already been comprehensively reviewed ((2) (3) (4) (5) (6) 
(7)), we will not discuss these further.  


	
Human cytomegalovirus (HCMV) is a beta7herpesvirus with a large (236 kbp) DNA 
genome that establishes life7long, usually asymptomatic, infection in healthy 
individuals. Significant interest in harnessing HCMV in vaccine vector development 
has stemmed from the observation that HCMV induces unusually large T cell 
responses (reviewed elsewhere (8)). Natural infection with HCMV elicits broad T cell 
responses directed to a vast array of antigens, with HCMV7specific responses 
comprising ~10% of the entire CD4+ and CD8+ T cell memory compartments (9). 
Although HCMV employs a vast array of immune evasion strategies to avoid control 
by the host immune system (reviewed in (10, 11)), HCMV7specific T cell responses 
are long7lived, with particularly high frequencies in elderly individuals (12). HCMV7
specific T cells also maintain functionality during virus chronicity and readily produce 
multiple effector molecules (e.g. IFN7γ, TNFα) upon stimulation (13) (14) and control 
virus replication  (15). Furthermore, experiments in the murine CMV (mCMV) 
model that recapitulates the accumulation of highly functional CMV7specific T cell 
over time (16) (17) (18) demonstrate that CMV infection triggers seeding of tissue7
resident memory T cells in peripheral, including mucosal, tissues (19) (20). Thus, 
although HCMV also induces substantial antibody responses upon infection (21), this 
virus represents a particularly exciting tool for inducing potent T cell immunity.  
 
HCMV exhibits several other properties attractive for viral vectors. CMV7based 
vectors can be engineered to express multiple exogenous immunogens (22) (23). 
HCMV also super7infects HCMV immune hosts (24). The immunogenicity of CMV7
based vaccines was first investigated using recombinant mCMV7based constructs. 
These induced accumulation of T cells reactive to peptides derived from 
heterologous antigens that, importantly, conferred protection from heterologous 
(vaccinia) viral challenge (25). Subsequently, induction of protective pathogen7
specific T cell responses by mCMV7based vectors has been demonstrated in 
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ebolavirus, herpes simplex virus and 	


challenge models 
(26) (27) (28) (29), although non7specific induction of NK cell responses partially 
contributes to early anti7mycobacterial activity of mCMV (28).  
 
Broad interest in HCMV7based vaccines was triggered by encouraging data from 
rhesus CMV (RhCMV)7based vaccines engineered to express antigens from simian 
immunodeficiency virus (SIV). Using vectors expressing SIV Gag, Env and a Rev7
Tat7Nef fusion protein, Picker and colleagues demonstrated vaccine7induced 
protection from mucosal SIV challenge that was associated with the development of 
effector memory T cell responses (22) (23). Whilst RhCMV7induced protection did 
not preclude SIV spread from mucosal sites of entry, progressive clearance of SIV in 
~50% macaques was reported, providing evidence that CMV7based vaccines may be 
exploited to induce protective anti7HIV immunity (30) (31).  
 
Analysis of RhCMV vaccine7induced T cell immunity revealed broad CD8+ T cell 
responses with an altered epitope hierarchy to responses induced by natural SIV 
infection. Intriguingly, RhCMV7induced CD8+ T cells were restricted by MHC class II 
(30) and HLA7E (32) rather than through classical MHC7Ia restriction. This unique 
induction of CD8+ T cell responses was attributed to deletion of the Rh157.5/4 genes 
within the fibroblast7adapted RhCMV vector (32). Rh157.5/4 are orthologs of the 
HCMV UL128/UL130 genes that encode components of the viral pentameric 
complex that is required for viral entry into non7fibroblast cells (33). How deletion of 
these genes leads to the induction of unique T cell responses is unclear. 
Interestingly, in a phase I trial in humans using chimeric HCMV viruses that lacked 
the pentameric complex, vaccine7induced CD8+ T cell responses exhibited classical 
MHC restriction (34). This may indicate key biological differences between RhCMV 
and HCMV, or may reflect the incomplete understanding of how RhCMV vectors elicit 
their unusual responses. It will be important to define the mechanisms that underpin 
the induction of these unusual T7cell responses, and to identify which responses are 
critical for protection, in order to generate human CMV vectors that are equally 
effective. 
 
CMV7based vectors are clearly exciting. However, HCMV is pathogenic, and 
attenuated vectors are necessary for translation into humans. In mice, temperature 
sensitive mCMV fails to induce robust virus7specific CD8+ T cell memory (35), 
eliminating this strategy from exploration for vector attenuation. Encouragingly, 
however, spread7deficient mCMV vectors lacking the surface glycoprotein L (36) or 
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the virion protein M94 (37) induce robust T cell immunity. Indeed, glycoprotein L7
deficient (gL) mCMV induces circulating effector memory7like CD8+ T cell 
responses, although the degree to which different mCMV7specific responses are 
induced varies substantially (36). Whether variation reflects the differential 
dependence of mCMV7specific CD8+ T cells on CD4+ T cell help (38) (39) (40) is 
unclear. Importantly, we observed that gL deficiency substantially impairs the 
seeding of multiple epitope7specific CD8+ T cell responses within peripheral tissues, 
and gL mCMV7induced CD8+ T cells exhibit sub7optimal recall responsiveness (Ian 
R Humphreys, unpublished observation). Thus, a greater understanding of how to 
safely induce potent T cell responses using CMV7based vectors will inform future 
strategies.  
 
Studying CMV7induced T cell immunity may also inform alternate vector7based 
vaccine strategies. Experiments with mCMV have suggested that antigen expression 
rather than peptide7intrinsic properties influence mCMV7induced T cell expansions 
(29). Furthermore, C7terminal localization of peptide in viral proteins greatly 
increases peptide availability for proteosomal processing and subsequent 
accumulation of protective peptide7specific T cell memory (41). Interestingly, 
adenovirus7based vectors engineered to express peptide mini7genes can induce 
effector memory T cell accumulations indicative of CMV7induced T cell immunity (42) 
(43). Thus, studies of CMV7induced T cell responses may inform the development of 
alternate viral vector systems capable of inducing robust effector memory T cell 
responses.  




	
	

Soon after their pioneering development as gene therapy vectors in the early 1990s, 
adenoviruses were also explored as vaccine vectors (44) and have been used in 
numerous clinical vaccine trials since 2003 (45). Thus, they are not considered novel 
vectors . However, in the past few years, several groups have made innovative 
improvements to adenoviral vectors which are worth exploring here as these are 
already, or have the potential to become, clinically relevant. The various 
enhancements broadly address two challenges: (i) overcoming pre7existing anti7
vector immunity and (ii) enhancing vaccine7induced antigen7specific immunogenicity. 
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Adenoviruses (Ads) are non7enveloped icosahedral viruses with 30740 kb linear DNA 
genomes, which can be genetically manipulated without difficulty. The antigen 
expression cassette is most often inserted into the E1 genomic locus, rendering the 
virus replication7deficient. Vectors in which nonessential E3 genes are also deleted 
can accommodate expression cassettes up to a size of 7 kb. Until recently, 
replication7deficient AdHu5 was the most widely used Ad vector in vaccine 
development, due to its ability to elicit exceptionally strong CD8+ T7cell and antibody 
responses, and the ability to generate high titers of virus during manufacturing. 
However, pre7existing immunity against this vector, specifically neutralizing antibody 
titer, was shown to correlate with a reduction in antigen7specific immunogenicity in 
clinical trials (46) (47). Many groups consequently explored adenoviruses with lower 
seroprevalence in the human population, such as different human Ad serotypes or 
simian Ads. Interestingly, different serotypes were found to elicit different 
immunogenicity profiles in mice with respect to phenotype, function and longevity of 
the cellular immune response (48). For example, the human adenoviral vectors Ad26 
and Ad35 induced enhanced memory CD8+ T cells and more polyfunctional CD8+ T 
cells as compared to Ad5 (48). These two alternative vectors (Ad26 and Ad35) have 
also been evaluated in clinical trials, with variable outcomes (49) (50) (51) (52). For 
example, Ad26 and Ad35 vectors containing the HIV71 env antigen were used in 
heterologous prime7boost combinations in a Phase I trial (53). The authors found that 
the Ad267Ad35 prime7boost elicited significantly higher antibody titers than the Ad357
Ad26 regimen, but T7cell responses were modest overall. Ad26 was also used as a 
priming vector in Ebola clinical trials, where together with an MVA boost, vaccination 
was able to elicit a strong and durable antibody response to the Ebola virus antigen 
(54) (55). Ad35 has additionally been evaluated in several other HIV vaccine trials 
(56) (51) (57) (58), where it was demonstrated to be safe and immunogenic. 
Furthermore, in a TB vaccine trial it was found to be safe in both infants and HIV+/7 
adults. However, it only elicited a cellular immune response upon repeated high dose 
vaccinations (49). 
 
In addition to human Ads, many simian Ad7based vaccine vectors have been tested 
pre7clinically, and five have advanced to clinical studies to date (59) (60) (61), with 
promising results. A prominent example is ChAd37EBOZ, a chimpanzee7adenoviral 
vector encoding the Ebola Zaire glycoprotein, which was evaluated in Phase I and II 
clinical trials in response to the recent Ebola epidemic (62) (63) (64). This vector was 
assessed with and without an MVA booster dose, and was found to elicit strong 
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antibody and T7cell responses which could be increased in magnitude and durability 
by an MVA boost. Another chimpanzee adenoviral vector, ChAd63, has also been 
evaluated in several clinical trials (malaria (65) (66) (67), leishmaniasis (68)) with 
results showing excellent safety and immunogenicity, even in infants and children. 
 
Improving transgene immunogenicity is also a significant focus of on7going studies. 
One strategy to enhance the immune response against exogenous antigen is to 
increase immunogen production from the vaccine vector. This is difficult to achieve 
with replication7deficient (E17deleted) Ad vectors, since antigen expression is 
restricted to the single copy of the vector genome present in the infected target cell. 
Increased antigen expression could be achieved by enabling the vector to self7
amplify in one additional round of genome replication after cell entry (so7called 
single7cycle Ads), or by using replication7competent adenoviruses. The former 
approach has been explored through deletion of a structural gene (pIIIa) from a 
replication7competent adenovirus (69) that renders the virus unable to spread. The 
subsequent virus expresses early viral genes and replicates its genome, producing 
~307100 fold more copies of the antigen expression cassette than replication7
deficient vectors. Impressively, a single7cycle Ad encoding influenza A hemagglutinin 
showed a significantly higher antibody induction than its replication7deficient 
equivalent, even at a 107fold lower dose (70, 71). One drawback of this method, 
however, is the requirement for a trans7complementing cell line (in this case 
expressing pIIIa) for the production of such a single7cycle Ad, which may represent a 
bottleneck for clinical development.  
 
To fully exploit the advantages of a self7amplifying vaccine, several groups have also 
examined the use of replication7competent Ad vectors, which were administered by 
varying mucosal routes in permissive species (mice are not permissive for human or 
simian adenoviruses.) Unfortunately, results with regard to induction of humoral 
immunity were mixed (72) (73) (74) or disappointing (75) (76) (77). One beneficial 
feature of replication7deficient adenoviral vectors is the fact that the transgene is 
typically immuno7dominant by default, since the lack of adenoviral gene expression 
precludes immune7competition. It is therefore likely that replication7competent 
vectors can only be effective vaccines if the transgene remains immuno7competent 
whilst competing with numerous other viral gene products; achieving this has been 
challenging (reviewed in (78)). Furthermore, replicating adenoviral vectors carry 
higher safety risks due to their ability to cause systemic infection in certain 
susceptible populations (79). However, whilst they are indeed not suitable for use in 
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the severely immunocompromised, a live (oral) adenovirus vaccine used to protect 
against respiratory disease caused by Ad4 and Ad7 has nevertheless long been 
used in the United States army, with a very good safety profile (80). 
 
In addition to exploiting vector amplification to increase antigen expression, several 
other methods have been described which aim to enhance the immunogenicity of 
adenoviral vectors. One of these approaches, antigen capsid7incorporation, has been 
particularly successful in preclinical studies (reviewed in (81)). Here, antigenic 
epitopes are incorporated into viral structural proteins in such a way that they are 
exposed on the virus surface and are therefore able to elicit robust antibody 
responses. Epitopes from a variety of different pathogens have been tested (e.g. 
HIV71 (82), influenza A (83),  
 (84)). One group, for example, 
demonstrated that a multivalent HIV71 vector based on AdHu5 elicited antibody 
responses to an externally presented HIV71 B7cell epitope, in addition to cellular 
response to the virally encoded HIV71 gag antigen (85). One clear disadvantage of 
this method is that only short heterologous sequences can be inserted into viral 
structural genes without affecting virus assembly or stability. As an exception, the 
adenoviral capsid protein pIX can accommodate C7terminal fusions with larger 
antigens. However, these fusions can have a destabilizing effect on the virion (86). 
Overall, considering the large numbers of publications reporting encouraging results, 
it is surprising that (to our knowledge) the capsid7display approach has not yet been 
evaluated in the clinic.  
 
 

		
The use of VSV as a vaccine vector was pioneered by Rose and colleagues in the 
late 1990s (87), and the vector has since been employed in numerous preclinical 
studies. However, due to the challenges encountered in developing a sufficiently 
attenuated, safe VSV backbone, a first7in7human evaluation of an rVSV vaccine did 
not take place until 2011 (88). This was soon followed by clinical trials of an rVSV7
vectored Ebola vaccine (2014), which was the most advanced vaccine candidate in 
the recent ebolavirus epidemic in West Africa. Buoyed by this success, the VSV 
vector has been the subject of much interest by numerous investigators.  
 
VSV is an enveloped bullet7shaped virus that belongs to the  family and 
contains an 11kb negative7sense RNA genome. Apart from its ability to induce robust 
cellular and humoral immunity against encoded transgenes, its high titer growth in 
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validated cell lines (e.g. Vero) and the lack of a DNA intermediate during viral 
replication add to its attractiveness as a vaccine vector. However, owing to its 
negative7sense RNA genome, rescue of recombinant virus from plasmid DNA is 
more challenging than rescue of DNA viruses, as it involves co7transfection of five 
plasmids into a permissive cell line (89). The cargo capacity of recombinant VSV 
vectors was found to be at least 4.5 kb (90), and its genomic structure conveniently 
allows insertion of transgenes at multiple sites, which will result in transgene 
expression at varying levels. Unlike adenoviral vectors (which are typically 
replication7deficient), most VSV vaccine vectors are replication7competent, albeit 
attenuated. Attenuation represents an important safety feature, as wild type VSV is 
neurovirulent upon intracranial inoculation (91). Attenuation of VSV can be achieved 
in several ways; the most prominent example combines down7regulation of N protein 
expression with truncation of the VSV7G cytoplasmic tail, resulting in the attenuated 
vector rVSVN4CT1, which has been approved for clinical studies (92).  
 
In the past 20 years, VSV vaccine vectors have been demonstrated to induce robust 
cellular and humoral immune response in numerous preclinical studies, leading to 
protection in many animal models of pathogen challenge, frequently after a single 
vector administration (reviewed in (93)). Durability of a protective immune response 
(up to one year thus far) has also been demonstrated (94). Since 2011, rVSV vectors 
have been evaluated in four completed or ongoing clinical trials for HIV71 (88) (95) 
(96) (97), and in Phase I and II and III trials for Ebola (reviewed in (98)).  Of note, the 
Phase III trial which took place during the 2014/15 outbreak in Guinea showed 
promising efficacy in a ring7vaccination strategy (99). Analysis of immunogenicity in 
these studies revealed a robust induction of neutralizing antibodies and a modest 
CD8+ response for all participants in the Ebola clinical trials (100), while the only 
report thus far of an HIV71 trial was more disappointing, with modest CD4+ levels in 
two thirds of participants and low antigen7specific antibody levels in one third of 
participants (88). Of interest, significant differences existed in the vector backbones 
used in these trials: rVSV7HIV71 vectors were attenuated by genetic engineering as 
mentioned above (containing the rVSVN4CT1 backbone) and the HIV71 antigen 
coding sequence was placed in position 1 of the genome. In contrast, the rVSV7
EBOV clinical vector was simply based on the cell culture adapted VSV Indiana 
strain lacking VSV7G (rVSV∆G), with the Ebola glycoprotein (EBOV7GP) placed in 
position 4. In the absence of the native glycoprotein, EBOV7GP acted as the vaccine 
antigen in addition to the viral entry protein. Since the VSV glycoprotein is the main 
determinant of viral tropism, safety considerations for the rVSV7EBOV vector are 
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different than those for the rVSV7HIV vectors. Indeed, in initial Phase I trials, 
replication of the rVSV7EBOV vector was detected in synovial fluid and skin lesions, 
most likely due to EBOV7GP specific tissue tropism (101).  
 
In an effort to address safety concerns, more attenuated, second generation rVSV7
EBOV vectors were recently developed (102). Attenuation was achieved by 
employing the rVSVN4CT1 backbone, and reduced virus growth was demonstrated 
in cell culture (102). The vaccine was still protective in a non7human primate Ebola 
challenge model after a single administration and, reassuringly, vaccination resulted 
in a 107 to 507fold reduction in vaccine7associated viremia in the blood as compared 
to first7generation vectors in previous studies. Unfortunately, this study did not 
include a direct comparison with first7generation rVSV7ZEBOV. However, a Phase I 
trial of this vaccine (rVSVN4CT17EBOVGP1) was recently completed (103), and thus 
insight into the safety profile of this vector will be soon available. In addition, 
GemEvac7Combi, an Ebola vaccine containing an rVSV expressing the Ebola GP, 
has also been developed (104). This vaccine was evaluated for safety and 
immunogenicity in a 2015 Phase I trial and subsequently licensed by the Ministry of 
Health of the Russian Federation. However, it is difficult to assess the potential 
impact of this vaccine, considering the paucity of published preclinical data and the 
lack of information regarding vector construction. A Phase 4 study of this vaccine 
involving 2,000 volunteers in Russia and Guinea is planned for 201772019  (105). 
 
In parallel with ongoing clinical studies, VSV vectors have been modified to further 
improve utility to create multivalent vectors. Mire   generated trivalent rVSV 
encoding glycoproteins from Zaire ebolavirus, Sudan ebolavirus and Marburg virus, 
and demonstrated protection against all three virus strains in a Guinea pig challenge 
model after a single immunization, even though antibody responses to each antigen 
differed in magnitude (106). Encouragingly, vectors containing ~6 kb transgenic 
cargo were generated, suggesting that multiple or large inserts can be incorporated 
into rVSV vectors. Another recent valuable observation regarding rVSV vector 
development is their ability to provide protection even after exposure to the 
pathogen. For example, full protection was shown when rhesus monkeys were 
vaccinated with an rVSV7MARV vector 30 minutes after receiving a lethal dose of 
Marburg virus (107), and five of six of animals were still protected when vaccinated 
24 hours after challenge (108). T cell depletion had no impact on vaccine7induced 
protection (109), suggesting that rapid induction of antibodies may underlie vaccine 
efficacy. Taken together, both preclinical and clinical studies suggest that the 
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strengths of the VSV vector lie in its attenuated replicative capacity and its ability to 
elicit high and durable antibody levels to surface7displayed antigens; characteristics 
which make it a promising vaccine vector for emerging or outbreak7prone viral 
diseases.    
 
 
	
Despite its pathogenicity, the development of measles virus as a vaccine vector was 
initiated in the late 1990s. This was based on the large success of the live attenuated 
measles vaccine itself. Measles vaccines were developed in the early 1960s by cell 
culture adaptation of wild type virus isolates, leading to attenuation via an 
accumulation of mutations. The most attenuated strains, still used today, have 
excellent safety profiles while still inducing extremely durable, protective antibody7 
and T7cell mediated immunity in 95% of recipients after a single vaccination (110) 
(111) (112). Interestingly, T7cell mediated responses to MV are predominantly of the 
CD4+ phenotype (113), unlike the CD8+ dominated response to adenoviral vectors 
(114), which may have important implications when considering these vector 
platforms for vaccine development.  
 
Measles virus, a member of the 	 family, is an enveloped spherical 
virus and contains a 16 kb negative7sense RNA genome. The development of 
reverse genetics tools and rescue of MV from cDNA in 1995 (115) accelerated both 
basic MV virology research and exploration of MV as a vaccine vector. Studies 
demonstrated a cargo capacity in excess of 6 kb and an excellent induction of 
humoral and cellular immune responses against encoded transgenes (116). In 
addition, MV was easily adaptable to large scale bio7manufacture, at low production 
cost. Recombinant MVs expressing one or more genes from heterologous pathogens 
have now been used in numerous preclinical vaccine studies (reviewed in (117)). 
One group, for example, generated an rMV expressing HIV71 Gag, RT and Nef as a 
fusion protein (MV17F4) and assessed immunogenicity of the vector in prime or 
prime7boost regimens in cynomolgus macaques (118). Vaccination induced robust 
antigen7specific CD4+ and modest CD8+ T7cell responses, and high levels of 
antibody reactive to exogenous antigens and MV7encoded proteins that were further 
amplified after boosting (118).  
 
During preclinical development, concerns arose regarding the impact of pre7existing 
immunity against the MV vector, as the live attenuated measles vaccine is part of 
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routine childhood immunization programs in many countries. However, higher doses 
or alternative administration routes of the vector can overcome existing anti7measles 
antibody levels in mice (119). Of note, in this study pre7existing immunity was 
artificially modeled using intra7venous administration of anti7measles antibodies. 
However, another study that examined prior exposure to attenuated measles vaccine 
found no influence of existing anti7MV immunity on transgene immunogenicity in 
mice or macaques (120). Another important consideration for the possible pediatric 
use of MV vectors is the requirement for the vector to retain vaccine competence 
against MV itself. This was indeed demonstrated in a macaque model using a MV7
based hepatitis B vaccine candidate (121). 
 
After almost two decades of preclinical development, MV vaccine vectors have 
recently been advanced into clinical trials, with two Phase I studies completed (HIV71 
(122), Chikungunya virus (CHIKV) (123)) and two Phase II CHIKV trials ongoing or 
planned in Europe and Puerto Rico, respectively (124) (125). In the Phase I CHIKV 
study, volunteers received escalating priming doses followed by a booster dose of an 
rMV encoding the structural genes (C, E3, E2, 6K and E1) of CHIKV, a mosquito7
borne alphavirus of the tropics and sub7tropics that is threatening to become a global 
public health burden. Protective immunity against CHIKV is antibody7mediated in a 
mouse model (126). Encouragingly, seroconversion was demonstrated for 90% of 
participants in the high dose group after one immunization, and for all participants 
after the second vaccination. In addition, immunogenicity was not affected by pre7
existing anti7measles immunity, an important finding which will hopefully be 
confirmed in larger ongoing studies. 
 
 

	 

Viral vectors hold much promise for vaccine vector development to counter infectious 
diseases. Significant advances have been made regarding the production of 
immunogenic vectors that can be used in individuals that have prior immunity to the 
viruses on which vectors are based. More detailed understanding of what immune 
responses are preferentially induced by vectors and how they are triggered will 
inform decisions as to which vectors are most relevant for vaccination against a 
specific infectious disease (Figure 1). Safety considerations remain a significant 
challenge in the development of certain viral vectors. This is relevant not only for 
vaccination against infectious diseases, but also for the potential exploitation of virus7
based vectors in cancer vaccination strategies where individuals are often immune 
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compromised. Thus, understanding better how to balance safety and immunogenicity 
will have broad implications for the management of infectious diseases and beyond. 
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